Source: http://www.google.com/patents/USRE39150?dq=5,241,671
Timestamp: 2016-06-28 10:41:26
Document Index: 432525016

Matched Legal Cases: ['art 1', 'art 2', 'art 1', 'art 2', 'art 1', 'art 2', 'Application No. 60']

Patent USRE39150 - Composition for creating vascular occlusions - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsA composition including 2-hexyl cyanoacrylate and goal is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked....http://www.google.com/patents/USRE39150?utm_source=gb-gplus-sharePatent USRE39150 - Composition for creating vascular occlusionsAdvanced Patent SearchPublication numberUSRE39150 E1Publication typeGrantApplication numberUS 09/823,775Publication dateJun 27, 2006Filing dateMar 30, 2001Priority dateSep 11, 1997Fee statusPaidAlso published asUS6037366, USRE42377Publication number09823775, 823775, US RE39150 E1, US RE39150E1, US-E1-RE39150, USRE39150 E1, USRE39150E1InventorsRobert E. Krall, Charles W. Kerber, Kimberly KnoxOriginal AssigneeProhold Technologies, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (13), Non-Patent Citations (17), Referenced by (4), Classifications (47), Legal Events (8) External Links: USPTO, USPTO Assignment, EspacenetComposition for creating vascular occlusions
US RE39150 E1Abstract
A composition including 2-hexyl cyanoacrylate and goal is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.
(a) Part 1 comprised of 2-hexyl cyanoacrylate, hydroquinone, p-methoxyphenol and phosphoric acid; and (b) Part 2 comprising gold metal powder, ethyl myristate and a sterilized a large chain fatty acid ester in liquid form and a stabilized polymer of 2-hexylcyanoacrylate in weak aqueous bicarbonate solution . 2. The composition of claim 1 wherein Part 1 comprises about 100 PPM hydroquinone, 100 PPM p-methoxyphenol, 250 PPM phosphoric acid and the remainder 2-hexyl cyanoacrylate.
3. The composition of claim 2 wherein Part 2 comprises about 65 percent by weight gold, about 30 percent by weight ethyl myristate and the remainder said sterilized stabilized polymer of 2-hexylcyanoacrylate in weak aqueous bicarbonate solut ion .
(a) Mixing together Part 1 comprised of 2-hexyl cyanoacrylate, hydroquinone, p-methoxyphenol and phosphoric acid with Part 2 comprising gold metal powder, ethyl myristate and a sterilized a large chain fatty acid ester in liquid form, and a stabilized polymer of 2-hexylcyanoacrylate in weak aqueous bicarbonate solution ; and (b) injecting administrating the mixture into a vascular site needing occlusion with the gold metal powder suspended in the mixture . Description
This application is a reissue of Ser. No. 09/159,621, filed Sep. 11, 1998, now U.S. Pat. No. 6,032,366, which claims the benefit of U.S. Provisional Application No. 60/058,510, filed on Sep. 11, 1997.
The product has a very slow rate of biodegradation. Both liquid and solid forms should have excellent cohesion. The delivered product should have medium adhesion The delivered product must be radiopaque. The solid polymer should be soft and pliable. The delivered product must have a very low or negligible histotoxicity. The deposited product must have no long term negative properties such as carcinogenicity, teratogenicity, systemic toxicity or other unpredictable biological and medical effects. The products must be sterile. The delivered product must have good few characteristics for selective catheterization. The product must be stable on storage for an extended period of time. The formulation should be made from pure products and be reproducible for simple manufacturing procedures.
*FMS is a specially prepared polymer of 2-hexyl cyanoacrylate and must be used within 24 hours of preparation or will change and be unusable. Further, it must be sterilized within 72 hours. Each item of this formulation is critical to the proper performance of the product.
FMS is the polymer of 2-hexyl cyanoacrylate formed in a weak, aqueous sodium bicarbonate solutions. The polymer diners in structure and size depending on how it is formed. This polymer will remain stable until M2 can be formulated. The polymer must be formed and dried completely before use. The final formulation of M2 must occur within 24 hours because the ethyl myristate stabilized FMS until sterilization can be performed. After sterilization the product is stable for several years.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4740534 *Aug 21, 1986Apr 26, 1988Sanyo Chemical Industries, Ltd.Surgical adhesiveUS5525334 *Mar 22, 1995Jun 11, 1996Japan As Represented By Director General Of Agency Of Industrial Science And TechnologyMethod for vascular embolizationUS5624685 *Apr 3, 1995Apr 29, 1997Terumo Kabushiki KaishaHigh polymer gel and vascular lesion embolizing material comprising the sameUS5695480 *Jul 29, 1996Dec 9, 1997Micro Therapeutics, Inc.Embolizing compositionsUS5702361 *Jan 31, 1996Dec 30, 1997Micro Therapeutics, Inc.Method for embolizing blood vesselsUS5759194 *Oct 23, 1996Jun 2, 1998Hemodynamics, Inc.Vascular patch applicatorUS5795331Jan 24, 1994Aug 18, 1998Micro Therapeutics, Inc.Balloon catheter for occluding aneurysms of branch vesselsUS6143352 *Sep 18, 1996Nov 7, 2000Closure Medical CorporationpH-modified biocompatible monomer and polymer compositionsUS6174919 *Feb 18, 1998Jan 16, 2001Closure Medical CorporationCyanoacrylate compositions with vinyl terminated ester groupsUS6476069 *Jan 29, 1999Nov 5, 2002Provasis Therapeutics Inc.Compositions for creating embolic agents and uses thereofUS20020018752 *May 23, 2001Feb 14, 2002Krall Robert E.Polymerizable compositions and methods of useUS20030194389 *Apr 12, 2002Oct 16, 2003Porter Stephen C.Occlusive compositionWO1999042535A1 *Jan 19, 1999Aug 26, 1999Closure Medical CorporationCyanoacrylate compositions with terminal vinyl group in the alcohol part* Cited by examinerNon-Patent CitationsReference1Barr, John D., "Temporary and Permanent Occlusion of Cerebral Arteries," Neuroendovascular Surgery, vol. 11, No. 1, Jan. 2000, pp. 27-38.2Berthelsen, B. et al., "Embolization of Cerebral Arteriovenous Malformations with Bucrylate," Acta Radiologica, vol. 31, 1990, pp. 13-21.3Freeny, Patrick C. et al., "Transcatheter Therapy of Genitourinary Abnormalities Using Isobutyl 2-Cyanoacrylate (Bucrylate)," AJR, vol. 133, Oct. 1979 pp. 647-656.4Gobin, Dr. Y. Pierre et al., "Treatment of Brain Arteriovenous Malformations by Embolization and Radiosurgery," J Neurosurg, vol. 85, 1996, pp. 19-28.5Halbach, Dr. Van V. et al., "Preoperative Balloon Occlusion of Arteriovenous Malformations," Neurosurgery, vol. 22, No. 2, 1988, pp. 301-308.6Kerber, Dr. Charles W. and Wong, Wade, "Liquid Acrylic Adhesive Agents in Interventional Neuroradiology," Neuroendovascular Surgery, vol. 11, No. 1, Jan. 2000, pp. 85-99.7Lefkowitz, Dr. Michael A. et al., "Balloon-assisted Guglielmi Detachable Coiling of Wide-necked Aneurysms: Part II-Clinical Results," Neurosurgery, vol. 45, No. 3, Sep. 1999, pp. 531-538.8Levy, Dr. David I., "Embolization of Wide-necked Anterior Communication Artery Aneurysm: Technical Note," Neurosurgery, vol. 41, No. 4, Oct. 1997, pp. 979-982.9Malek, Dr. Adel M. et al., "Balloon-assist Technique for Endovascular Coil Embolization of Geometrically Difficult Intracranial Aneurysms," Neurosurgery, vol. 46, No. 6, Jun. 2000, pp. 1397-1407.10Mericle, Robert A., M.D., "Temporary Balloon Protection as an Adjunct to Endosaccular Coiling of Wide-necked Cerebral Aneurysms", Neurosurgery, vol. 41, No. 4, Oct. 1997, pp. 1992-1998.11Moret, J et al., "The "Remodeling Technique" in the Treatment of Wide Neck Intracranial Aneurysms," Interventional Neuroradiology, vol. 3, 1997, pp. 21-35.12Pelz, David M. et al., "Preoperative Embolization of Brain AVMs with Isobutyl-2 Cyanoacrylate," AJNR, vol. 9, Aug. 1988, pp. 757-764.13Rao, V.R.K. et al., "Dissolution of Isobutyl 2-Cyanoacrylate on Long-Term Follow-Up," AJNR, vol. 10, Jan./Feb. 1989, pp. 135-141.14Spiegel, S. M. et al., "Adjusting the Polymerization Time of Isobutyl-2 Cyanoacrylate," American Journal of Neuroradiology, vol. 7, Jan./Feb. 1986, pp. 109-112.15Vinuela, F.V. et al., "Dominant-Hemisphere Arteriovenous Malformations: Therapeutic Embolization with Isobutyl-2-Cyanoacrylate," AJNR, vol. 4, Jul./Aug. 1983, pp. 959-966.16Vinuela, Fernando et al., "Angiographic Follow-Up of Large Cerebral AVMs Incompletely Embolized with Isobutyl-2-Cyanoacrylate," AJNR, vol. 7, Sep./Oct. 1986, pp. 919-925.17Vinuela, Fernando et al., "Progressive Thrombosis of Brain Arteriovenous Malformations After Embolization with Isobutyl 2-Cyanoacrylate," AJNR, vol. 4, Nov./Dec. 1983, pp. 1233-1238.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS20080241249 *Mar 30, 2007Oct 2, 2008Closure Medical CorporationCyanoacrylate compositeUS20090257976 *Nov 10, 2008Oct 15, 2009Valor Medical, Inc.Single vial formulation for medical grade cyanoacrylateUS20100144895 *Feb 17, 2010Jun 10, 2010Boston Scientific Scimed, Inc.Embolic compositions with non-cyanoacrylate rheology modifying agentsUSRE42377 *Jul 12, 2007May 17, 2011Stryker CorporationComposition for creating vascular occlusions* Cited by examinerClassifications U.S. Classification514/527, 424/605, 514/970, 424/601, 424/649, 514/944, 424/617, 424/78.37, 514/690, 424/78.31, 514/730, 514/834, 424/78.08, 514/930, 604/500, 424/78.35, 514/558, 514/824, 424/422, 514/526, 514/560International ClassificationA61K31/275, A61K31/12, A61L31/04, A61K33/42, A61L24/06, A61K33/24, A61K31/05, C09J4/00Cooperative ClassificationY10S514/93, Y10S514/944, Y10S514/834, Y10S514/824, Y10S514/97, A61K31/05, A61K33/24, A61L24/001, A61K31/122, C09J4/00, A61L2430/36, A61L24/06European ClassificationA61L24/00H, A61L24/06, A61K31/122, A61K33/24, A61K31/05, C09J4/00Legal EventsDateCodeEventDescriptionDec 30, 2004ASAssignmentOwner name: HUB PROPERTIES TRUST, MASSACHUSETTSFree format text: JUDGMENT LIEN;ASSIGNOR:PROVASIS THERAPEUTICS, INC.;REEL/FRAME:015503/0037Effective date: 20041217Jan 21, 2005ASAssignmentOwner name: PROVASIS THERAPEUTICS, INC., PENNSYLVANIAFree format text: CHANGE OF NAME;ASSIGNORS:PROHOLD TECHNOLOGIES, INC.;PROHOLD MEDICAL CORPORATION;REEL/FRAME:015583/0694;SIGNING DATES FROM 19980812 TO 20001207May 25, 2005ASAssignmentOwner name: BOSTON SCIENTIFIC CORPORATION, MASSACHUSETTSFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROVASIS THERAPEUTICS, INC.;REEL/FRAME:016274/0547Effective date: 20050228Aug 20, 2007FPAYFee paymentYear of fee payment: 8Mar 15, 2011ASAssignmentOwner name: STRYKER CORPORATION, MICHIGANFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOSTON SCIENTIFIC CORPORATION;REEL/FRAME:025959/0196Effective date: 20110103Owner name: STRYKER NV OPERATIONS LIMITED, IRELANDFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BOSTON SCIENTIFIC CORPORATION;REEL/FRAME:025959/0196Effective date: 20110103Aug 18, 2011FPAYFee paymentYear of fee payment: 12Nov 23, 2015ASAssignmentOwner name: STRYKER MEDTECH LIMITED, MALTAFree format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:STRYKER NV OPERATIONS LIMITED;REEL/FRAME:037153/0034Effective date: 20151013Owner name: STRYKER EUROPEAN HOLDINGS I, LLC, MICHIGANFree format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:STRYKER MEDTECH LIMITED;REEL/FRAME:037153/0241Effective date: 20151013Mar 8, 2016ASAssignmentOwner name: STRYKER EUROPEAN HOLDINGS I, LLC, MICHIGANFree format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT LISTED SERIAL NOS. 09/905,670 AND 07/092,079 PREVIOUSLY RECORDED AT REEL: 037153 FRAME: 0241. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT EFFECTIVE DATE 9/29/2014;ASSIGNOR:STRYKER MEDTECH LIMITED;REEL/FRAME:038043/0011Effective date: 20151013Owner name: STRYKER MEDTECH LIMITED, MALTAFree format text: CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL # 09/905,670 AND 07/092,079 PREVIOUSLY RECORDED AT REEL: 037153 FRAME: 0034. ASSIGNOR(S) HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:STRYKER NV OPERATIONS LIMITED;REEL/FRAME:038039/0001Effective date: 20151013RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services